Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1417–1440 of 54,948 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Hyperglycemia
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Small Cell Lung Cancer, Lung Cancer, SCLC
Interventions: Pazopanib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Asthma in Children, Nonadherence, Medication
Interventions: Maintenance ICS and Symptom Driven SABA, Symptom-driven budesonide/formoterol combination; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 12 Years to 17 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Leukemia, Other
Interventions: Not listed
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 5
States / cities: Miami, Florida • Miami Beach, Florida • Rochester, Minnesota + 2 more

Conditions: Breast Neoplasms
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Female only
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Progressive Glioblastoma, Recurrent Glioblastoma
Interventions: Biopsy Procedure, Biospecimen Collection, Lomustine, Magnetic Resonance Imaging, Nivolumab, Relatlimab, Surgical Procedure; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 325
States / cities: Jonesboro, Arkansas • Auburn, California • Duarte, California + 252 more

Conditions: Melanoma
Interventions: Melaxin (autologous dendritoma vaccine) and BCG; Biological
Lead sponsor: Prisma Health-Upstate; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-Cell
Interventions: Allogeneic stem cell transplant, Anti-CD19-chimeric-antigen-receptor-transduced T cells, Leukapheresis; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Male Factor Infertility
Interventions: PICSI dish; Device
Lead sponsor: Biocoat; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 801 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 9
States / cities: Laguna Hills, California • San Ramon, California • Atlanta, Georgia + 5 more

Conditions: Hematologic Malignancy
Interventions: AM4113-N5UT Dino-Lite; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Advanced Malignant Solid Neoplasm
Interventions: Interview, Palliative Therapy, Quality-of-Life Assessment, Questionnaire Administration; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsed or Resistant Acute Leukaemias
Interventions: LBS-007; Drug
Lead sponsor: Lin BioScience, Inc; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 5
States / cities: Tampa, Florida • Chicago, Illinois • Fairway, Kansas + 2 more

Conditions: Moderate to Severe Chronic Plaque Psoriasis
Interventions: AbGn-168H, placebo; Biological
Lead sponsor: AbGenomics B.V Taiwan Branch; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Boynton Beach, Florida + 11 more

Conditions: AML, MDS
Interventions: CYC065, Venetoclax; Drug
Lead sponsor: Cyclacel Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cystic Fibrosis-related Diabetes
Interventions: Insulin, Continuous glucose monitor (CGM); Drug · Device
Lead sponsor: Jagdeesh Ullal; Other
Eligibility: 18 Years to 80 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Corona Virus Infection, Flu Vaccine, Immunity
Interventions: Flu shot; Biological
Lead sponsor: Stanford University; Other
Eligibility: 9 Years to 64 Years
Enrollment: 230 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
Interventions: Laboratory Biomarker Analysis, Tipifarnib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2017
U.S. locations: 2
States / cities: Iowa City, Iowa • Rochester, Minnesota

Conditions: Extraocular Retinoblastoma
Interventions: Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Radiation Therapy, Thiotepa, Vincristine Sulfate; Procedure · Drug · Biological + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 10 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 47 more

Conditions: Muscle Weakness
Interventions: Neuromuscular electrical Stimulation (NMES), Sham Stimulation; Device
Lead sponsor: RML Specialty Hospital; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Hinsdale, Illinois

Conditions: Acute Respiratory Distress Syndrome (ARDS), Post Intensive Care Syndrome (PICS)
Interventions: An ICU admission and a temporally related ARDS diagnosis; Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 640,058 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 1,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Murfreesboro, Tennessee

Conditions: Bipolar I Disorder, Alcohol Dependence
Interventions: Quetiapine fumarate, lithium, divalproex; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 38
States / cities: Cerritos, California • San Diego, California • New Haven, Connecticut + 35 more

Conditions: Colon Cancer, Colorectal Cancer
Interventions: MRTX849, Irinotecan, Cetuximab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia, Cancer, Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin
Interventions: Ara C, Mesna, Cyclophosphamide, TBI-Total Body Irradiation; Drug · Radiation
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Up to 64 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

TPN-Induced Hyperglycemia: Impact on Clinical Outcome in Intensive Care Unit (ICU) and Non-ICU Patients

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

Symptom-driven ICS/LABA Therapy for Adolescent Patients With Asthma Non-adherent to Daily Maintenance Inhalers

Hairy Cell Leukemia Patient Data Registry

Analysis of Brain Metastasis in Patients With Breast Cancer, With and Without Over-Expression of HER-2

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Effectiveness of the Use of the PICSI Dish (Hyaluronan Microdot) in the Selection of Sperm for Intracytoplasmic Sperm Injection (ICSI)

Non Invasive Optical Imaging of WBC Count

Technology-Enhanced Palliative Care for Advanced Cancer Patients

The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias

Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Comparison of Meal-Time Dosing of Insulin in Cystic Fibrosis Related Diabetes

Understanding Immunity to the Flu Vaccine in COVID-19 Patients

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Facilitating Functional Independence in Patients Receiving Prolonged Mechanical Ventilation

An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

T-Regulatory Cell Kinetics, Stem Cell Transplantation, REGKINE